NCTN Genitourinary Cancer Trials Portfolio (Open as of 8/15/2022)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.
NCTN Genitourinary Cancer Trials Portfolio (Open as of 8/15/2022)
Each box below includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

Cross-disease trials:

- EAY131 (MATCH)
- S1609 (DART)
## NCTN Genitourinary Cancer Trials (Open as of 8/15/2022)

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>A031102</td>
<td>III</td>
<td>A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors</td>
</tr>
<tr>
<td>A031701</td>
<td>II</td>
<td>A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations</td>
</tr>
<tr>
<td>A031702</td>
<td>II</td>
<td>Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors</td>
</tr>
<tr>
<td>A031704</td>
<td>III</td>
<td>PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)</td>
</tr>
<tr>
<td>A031801</td>
<td>II</td>
<td>A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)</td>
</tr>
<tr>
<td>A031803</td>
<td>II</td>
<td>Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>A031901</td>
<td>II</td>
<td>Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial</td>
</tr>
<tr>
<td>A031902</td>
<td>II</td>
<td>CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer</td>
</tr>
<tr>
<td>A032001</td>
<td>III</td>
<td>MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer</td>
</tr>
<tr>
<td>A032002</td>
<td>II</td>
<td>Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)</td>
</tr>
<tr>
<td>A032101</td>
<td>II</td>
<td>A Phase 2 Trial of ADT Interruption in Patients Who Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM</td>
</tr>
<tr>
<td>AREN1721</td>
<td>II</td>
<td>A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups</td>
</tr>
<tr>
<td>EA8134</td>
<td>III</td>
<td>InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)</td>
</tr>
<tr>
<td>EA8171</td>
<td>II</td>
<td>Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer</td>
</tr>
<tr>
<td>EA8183</td>
<td>III</td>
<td>A Phase III Double Blinded Study of Early Intervention After RADICAL Prostatectomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)</td>
</tr>
<tr>
<td>EA8185</td>
<td>II</td>
<td>Phase 2 Study of Bladder-Sparing Chemoradiotherapy with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)</td>
</tr>
<tr>
<td>EA8191</td>
<td>III</td>
<td>Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence</td>
</tr>
<tr>
<td>EA8192</td>
<td>II/III</td>
<td>A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy</td>
</tr>
<tr>
<td>NRG-GU002</td>
<td>II/III</td>
<td>Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel</td>
</tr>
<tr>
<td>NRG-GU007</td>
<td>II</td>
<td>Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)</td>
</tr>
<tr>
<td>NRG-GU008</td>
<td>III</td>
<td>Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*)</td>
</tr>
<tr>
<td>NRG-GU009</td>
<td>III</td>
<td>Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)</td>
</tr>
<tr>
<td>NRG-GU010</td>
<td>III</td>
<td>Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)</td>
</tr>
<tr>
<td>NRG-GU011</td>
<td>II</td>
<td>A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadioTherapy with or without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)</td>
</tr>
<tr>
<td>NRG-GU012</td>
<td>II</td>
<td>Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)</td>
</tr>
<tr>
<td>S1802</td>
<td>III</td>
<td>Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer</td>
</tr>
<tr>
<td>S1806</td>
<td>III</td>
<td>Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>S1931</td>
<td>III</td>
<td>Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)</td>
</tr>
<tr>
<td>S1937</td>
<td>III</td>
<td>A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDLL Therapy</td>
</tr>
<tr>
<td>S2011</td>
<td>II</td>
<td>Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL</td>
</tr>
<tr>
<td>S2012</td>
<td>II/III</td>
<td>Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapolumonary Small Cell Neuroendocrine Carcinomas (NEC)</td>
</tr>
<tr>
<td>EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>S1609</td>
<td>II</td>
<td>DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors</td>
</tr>
</tbody>
</table>

This portfolio shows NCTN trials. For information about NCORP trials, please see: [https://ncorp.cancer.gov/find-a-study/](https://ncorp.cancer.gov/find-a-study/)